Anti-infective agents and hepatic disease.
Numerous factors such as changes in plasma protein binding, tissue binding, hepatic blood flow, hepatic metabolism, and distribution may occur in hepatic disease. The impact of these physiologic changes on pharmacokinetic and pharmacodynamic parameters of anti-infective agents is likely to be clinically significant. Unfortunately, these issues have not been thoroughly investigated. Even within the same type of liver disease, there is considerable interpatient variability in pharmacokinetic variables, rendering it difficult to predict drug disposition accurately. Pharmacokinetics of selected anti-infective agents are altered in hepatic disease, necessitating careful monitoring and dosage titration to avoid enhanced drug concentrations and risk of toxicity.
Tschida
S J
SJ
University of Minnesota College of Pharmacy, Minneapolis, USA.
Vance-Bryan
K
K
Zaske
D E
DE
D000890:Anti-Infective Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002701:Chloramphenicol / Q000493:pharmacokinetics; D002981:Clindamycin / Q000493:pharmacokinetics; D024841:Fluoroquinolones; D006801:Humans; D007538:Isoniazid / Q000493:pharmacokinetics; D008107:Liver Diseases / Q000188:drug therapy* / Q000378:metabolism; D008657:Metabolic Clearance Rate; D012293:Rifampin / Q000493:pharmacokinetics
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D002981:Clindamycin; D002701:Chloramphenicol; D007538:Isoniazid; D012293:Rifampin